HOME >> BIOLOGY >> NEWS
Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM

San Diego, CA, September 27, 1998 - Clinical investigators today presented Phase III clinical trial data for the HIV protease inhibitor Agenerase` (amprenavir) which suggest that the drug may be potent and generally well-tolerated in combination with Epivir" (lamivudine) also known as 3TC", and Retrovir" (zidovudine; AZT). These data, presented at a late-breaker slide session at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) support the role of Agenerase in front-line combination antiretroviral therapy.

An as-treated analysis of interim 16 week data showed that 88% of patients taking triple therapy with Agenerase+Epivir+Retrovir achieved viral load below the limit of detection of standard assays (<400 copies/mL), compared to 19% of patients taking Epivir+Retrovir alone. An additional analysis showed that 59% of patients receiving this regimen achieved viral load below the limit of detection of an investigational ultrasensitive assay1 (<50 copies). An as-treated analysis evaluates only those patients who remain on study medication through the entire study period.

"In this trial, Agenerase appears to provide a significant amount of virus suppression when given in combination with two reverse transcriptase inhibitors," said Dr. Jeffrey Goodgame, M.D., lead investigator for the study and Associate Professor at the University of Central Florida. "Data generated in smaller studies have supported the potential clinical utility of Agenerase in a number of different regimens, including dual protease inhibitor combinations."

Agenerase (formerly known as 141W94 or VX-478) is a second-generation protease inhibitor that is now being made available in the United States to certain patients through an early access program. Phase III data presented today are intended to support applications to be submitted later in the fall by Vertex's partner Glaxo Wellcome for approval to market Agenerase in the United States and the European
'"/>

Contact: Michael Partridge
partridge@vpharm.com
(617) 577-6108
Vertex Pharmaceuticals
27-Sep-1998


Page: 1 2 3 4 5

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. OneWorld Health completes enrollment, treatment in Phase III India trial
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. KEPPRA international Phase IV SKATE study results show favourable efficacy
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
11. Phase transition in bilayers could affect their performance

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... , ... Serialization deadlines in the US and European Union ... becomes fully applied in the United States in 2023, pharmaceutical companies are scrutinizing ... most regulations?including the Drug Supply Chain Security Act (DSCSA)?have required minimal system capabilities. ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Join Jonathan Riek, ... session on Tuesday, September 10, 2019 at 1pm EDT to learn about two ... effective management. , NAFLD is the most common diffuse liver disease, with a ...
(Date:8/14/2019)... ... , ... Dr. Julie Reck of Veterinary Medical Center of Fort Mill has recently ... cell patient, her own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis ... but his body was weak, and he struggled to play fetch and other games with ...
Breaking Biology News(10 mins):
(Date:8/8/2019)... ... August 08, 2019 , ... Inference Solutions , a ... today announced that the company’s Studio Intelligent Virtual Agent (IVA) platform earned ... will officially accept the award at Frost & Sullivan’s annual Excellence in Best ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... populations down to the strain level, has announced partnerships with six international distributors. ... to companies and research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New ...
(Date:8/4/2019)... , ... August 02, 2019 , ... Cirtec Medical Corporation, ... devices, today announced that it has begun construction on a 30,000 sq. ft. ... miles from San Jose. , The facility, which is expected to be fully ...
(Date:7/23/2019)... ... July 22, 2019 , ... While today ... in the fields of 3D tissue imaging , digital pathology , ... started back in 2013 as a products company. These products are focused on ...
Breaking Biology Technology:
Cached News: